An update from CStone Pharmaceuticals ( (HK:2616) ) is now available.
CStone Pharmaceuticals recently presented five preclinical studies at the 2025 AACR Annual Meeting, showcasing advancements in their innovative cancer therapy pipeline. Key highlights include the trispecific antibody CS2009, which targets PD-1, VEGFA, and CTLA-4, showing potential as a next-generation immune-oncology treatment with enhanced anti-tumor efficacy. Additionally, the bispecific antibody CS2011 demonstrated strong binding affinity to EGFR and HER3, effectively inhibiting tumor growth in various cancers. These developments underscore CStone’s commitment to advancing cancer treatment and potentially improving outcomes for patients.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing innovative cancer therapies. The company specializes in creating antibody-based treatments, including trispecific and bispecific antibodies, as well as antibody-drug conjugates, aimed at addressing various types of cancers.
YTD Price Performance: 26.09%
Average Trading Volume: 7,119,039
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.89B
For an in-depth examination of 2616 stock, go to TipRanks’ Stock Analysis page.